Local legends

Houston-based medical device companies pitch at TMCx Demo Day

Four Houston companies showed the city what they're made of at TMCx's recent Demo Day. Courtesy of TMCx

Earlier this month, 16 medical device companies wrapped up their time at the Texas Medical Center's accelerator program and pitched their companies to fellow health professionals, guests, and more. While each made important connections in the local ecosystem during the program, a quarter of the entrepreneurs had roots in Houston already.

Four of the 16 TMCx09 companies that are headquartered in Houston. They have built solutions within sepsis, surgery, and transplant spaces in health care. Here's a little more about the homegrown companies that pitched at the event.

CorInnova

Photo via corinnova.com

The standard practice for acute heart failure patients is very invasive, says William Altman, CEO of CorInnova.

"The problem with existing devices is that they have invasive blood contact," Altman says. "Problem with that is blood contact is bad. It can cause up to 15 percent rate of stroke, which could kill you, and after five to seven days it provides 10 percent rate of blood destruction and has a 47 percent rate of kidney disfunction."

CorInnova's technology features a device that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping by 50 percent.

"Surgeons tell us this is less invasive than minimally invasive aortic valve replacement, which is a widely done surgery, so this promises widespread adoption for our technology as we get it approved," Altman says.

The human prototype is expected to be ready in two years, with the next year being focused on animal studies. CorInnova is raising $12 million to accomplish its goals.

Ictero Medical

Getty Images

An estimated 10 to 15 percent of the United States population will get a gallstone in their lifetime. Should one of those stones cause trouble or blockages, the only solution is to remove the gallbladder completely through surgery. However, Matthew Nojoomi, CEO and co-founder of Ictero Medical, has another idea.

Ictero Medical has created a minimally invasive treatment that uses cryoablation to defunctionize the gallbladder without having to remove it.

"The CholeSafe System not only treats the source of the disease, but it leverages existing clinical workflows that doctors use to access the gallbladder," says Nojoomi, adding that the process only uses mild station and pain control.

The company expects to get to humans in the next two years, and has launched a financing round.

PATH EX

path ex

Photo via tmc.com

Currently, sepsis is hard to identify in patience. Even if a patient is in a hospital, and that hospital knows the patient has sepsis, the individual still has a 38 percent chance of dying, says Sinead Miller, CEO of PATH EX.

"Right now the problems associated with sepsis are very clear," she says. "It's the leading cause of death in our ICUs, and it's also associated with the highest hospital cost and readmission rates."

PATH EX's technology allows medical professionals to better diagnose and treat sepsis. The PATH EX therapeutic device can be hooked up to a patient and flow his or her blood through the machine to capture bacteria, clean and recirculate the blood, and faster diagnose what sort of bacteria the patient has attracted. The device technology is similar to hemo hemodialysis, Miller explains.

The Houston company, which recently won big at the Ignite Healthcare Network's Fire Pitch Competition, was named an honoree within the Johnson and Johnson Breakthrough Medical Technologies Quickfire Challenge.

The company was recently received clearance from the Food and Drug Administration as a breakthrough device technology. PATH EX closed its $615,000 seed round — with plans for a series A next year — and has received $1 million in SBIR grant funding. The company was founded two years ago, and relocated to call Houston HQ this year.

Volumetric

Jordan Miller/Rice University

Volumetric is banking on their technology being among the inventions that will lead the medical industry into the future. The human tissue-printing technology company has created the 3D printer and the "ink" that can create whole organs for transplant.

"We can create complicated vascular architectures inside of soft water-based gels, in this case, mimicking the structure and function of human lung tissue," says Jordan Miller, CEO. "We can oxygenate red blood cells."

The company is commercializing its technology and has three streams of revenue, which as generated almost $1 million in revenue in Volumetric's second year. The company is also in the process of closing its seed round of fundraising.

Earlier this year, the startup, which works out of Rice University, was featured on the cover of Science magazine.

This week's set of who's who include a startup founder trying to change the world, a passionate PhD with a story of failure to tell, and a biomedical engineer enhancing health tech in Houston. Courtesy photos

Another set of female innovation leaders are making headlines as we move into another week of innovators to know.

This week's set of who's who include a startup founder trying to change the world, a passionate PhD with a story of failure to tell, and a biomedical engineer enhancing health tech in Houston.

Ana Carolina Rojas Bastidas, founder of Orolait

orolait

A Houston mom is working hard on her startup so that next summer, breastfeeding moms can swim in style and worry free. Courtesy of Orolait

On the surface, it may seem that Houston mom Ana Carolina Rojas Bastidas has a passion for fashion, as she's created and is fundraising for a new-mom specific line of swimwear. But really, she's on a mission to give breastfeeding women back their dignity with her startup, Orolait.

"I decided to build this company to challenge and change the way we depict one's breastfeeding journey," Bastidas says on the website. "I stand on the pillars of advocacy, education, and inclusion. You will see the sizing and advertising featuring all shapes, sizes, and shades because each of us is so different and that is what makes us so incredible and I am going to unapologetically celebrate that in the most ethical way I know how." Read the story.

Brittany Barreto, venture associate at Capital Factory

Brittany Barreto

Brittany Barreto founded the first nationwide DNA-based dating app, and she shares her story of its unexpected, and unavoidable, downfall. Photo courtesy of Pheramor

After dedicating three long years to her startup that began as an idea in college, Brittney Barreto is saying goodbye to Pheramor. Barreto explains how her DNA-based dating app got pulled from the Apple app store following policy changes, and how it left her with no choice but to shutter the operation.

Now, Barreto has big plans for funding femtech, and is learning a lot in her new role at Capital Factory. She's already able to do more for other founders and create a bigger impact.

"I realized that over the past two years, I had already been ad hoc coaching and mentoring founders and loving it," Barreto says. "Now, I was doing it and getting paid for it, on a bigger scale, and with more resources. I knew it was the journey I wanted to continue down." Read the full story.

Emily Reiser, senior manager of innovation community engagement at TMC

Emily Reiser

From robots and accelerator programs to her favorite health tech startups, Emily Reiser of the TMC Innovation Institute joins the Houston Innovators Podcast. Photo courtesy of Emily Reiser

Emily Reiser has known for most of her life that she's wanted to work in health tech — in some capacity. On the Houston Innovators Podcast, she explains how she combined her early interest in health care with her affinity with engineering inspired by her parents.

Now, she continues to check both those boxes at the Texas Medical Center's Innovation Institute, which has evolved a ton over the past year.

"In 2019, we had a lot of big changes around our team and our leadership," she says on the podcast. "That enabled us to take a bigger breath and a bigger pause to say, 'How are we really doing? And how could we be doing better?'" Read the full story and stream the podcast.